Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Pyxis Oncology Inc (PYXS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: PYXS (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 176.36% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 64.96M USD | Price to earnings Ratio - | 1Y Target Price 6.8 |
Price to earnings Ratio - | 1Y Target Price 6.8 | ||
Volume (30-day avg) 591175 | Beta 1.11 | 52 Weeks Range 0.91 - 6.18 | Updated Date 04/1/2025 |
52 Weeks Range 0.91 - 6.18 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.32 |
Earnings Date
Report Date 2025-03-18 | When - | Estimate -0.33 | Actual -0.2622 |
Profitability
Profit Margin - | Operating Margin (TTM) -406.11% |
Management Effectiveness
Return on Assets (TTM) -24.77% | Return on Equity (TTM) -62.76% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -46076760 | Price to Sales(TTM) 4.02 |
Enterprise Value -46076760 | Price to Sales(TTM) 4.02 | ||
Enterprise Value to Revenue 5.08 | Enterprise Value to EBITDA 1.09 | Shares Outstanding 61590400 | Shares Floating 44339556 |
Shares Outstanding 61590400 | Shares Floating 44339556 | ||
Percent Insiders 23.72 | Percent Institutions 40.09 |
Analyst Ratings
Rating 4.5 | Target Price 8.83 | Buy 2 | Strong Buy 5 |
Buy 2 | Strong Buy 5 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Pyxis Oncology Inc
Company Overview
History and Background
Pyxis Oncology Inc. is a clinical-stage oncology company focused on developing next-generation antibody-drug conjugates (ADCs) and immunotherapies to treat difficult-to-treat cancers. It was founded in 2019 and is headquartered in Cambridge, Massachusetts. The company went public in 2021. Pyxis is focused on advancing a portfolio of novel therapies that address unmet needs in cancer treatment.
Core Business Areas
- ADC Development: Pyxis focuses on developing antibody-drug conjugates (ADCs), which deliver cytotoxic agents directly to cancer cells, minimizing damage to healthy tissues.
- Immunotherapy Development: The company is developing immunotherapies designed to enhance the body's immune response to fight cancer.
- Research and Development: Pyxis invests heavily in research and development to discover and develop novel oncology therapeutics.
Leadership and Structure
Lara S. Sullivan, M.D., is the President and CEO. The leadership team includes executives in research, development, finance, and operations. The company has a board of directors with expertise in oncology and biotechnology.
Top Products and Market Share
Key Offerings
- PYX-106: An anti-Siglec-15 antibody designed to reprogram the tumor microenvironment and enhance anti-tumor immunity. It is currently in Phase 1 clinical trials. Competitors include companies developing similar immuno-oncology therapies, such as Merck, Bristol Myers Squibb, and Roche.
- PYX-201: An antibody-drug conjugate (ADC) targeting Fibroblast Activation Protein Alpha (FAPu03b1) which is highly expressed in the tumor microenvironment and certain tumors. It is currently in Phase 1 clinical trials. Competitors include companies developing other FAP-targeting therapies, such as BioNTech and other ADC companies.
- PYX-203: An ENPP1 Inhibitor targeting ENPP1. It is currently in preclinical stages.
Market Dynamics
Industry Overview
The oncology market is rapidly growing, driven by increasing cancer incidence, aging populations, and advancements in cancer diagnostics and therapeutics. The market is highly competitive, with numerous companies developing novel therapies.
Positioning
Pyxis Oncology is positioned as an innovative oncology company focused on developing next-generation ADCs and immunotherapies. Its competitive advantage lies in its novel therapeutic targets and ADC technology.
Total Addressable Market (TAM)
The global oncology market is estimated to be worth hundreds of billions of dollars. Pyxis Oncology is targeting specific segments of this market with its novel therapies, giving it access to a significant portion of the overall TAM.
Upturn SWOT Analysis
Strengths
- Novel therapeutic targets
- ADC technology platform
- Experienced leadership team
- Strong focus on research and development
Weaknesses
- Early-stage clinical development programs
- Limited financial resources compared to larger pharmaceutical companies
- Reliance on successful clinical trial outcomes
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of product pipeline
- Positive clinical trial results
- Growing oncology market
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Economic downturn
Competitors and Market Share
Key Competitors
- MRK
- BMY
- RHHBY
- BNTX
Competitive Landscape
Pyxis Oncology faces intense competition from established pharmaceutical companies and other biotechnology companies developing oncology therapies. Its advantages include its novel therapeutic targets and ADC technology, while its disadvantages include its limited financial resources and early-stage clinical development programs.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by the company's progress in advancing its pipeline of ADC and immunotherapy candidates. It is dependent on results from Phase 1 clinical trials for the PYX products.
Future Projections: Future growth is dependent on successful clinical trial outcomes, regulatory approvals, and commercialization of its therapies. Analyst estimates may vary. Please refer to financial data providers for projections.
Recent Initiatives: Recent initiatives include advancing its clinical programs, expanding its research and development efforts, and securing partnerships to support its growth.
Summary
Pyxis Oncology is a clinical-stage company focused on developing novel cancer therapies, particularly ADCs and immunotherapies. While the company has promising technologies and a focused strategy, it is still early in its development and faces significant risks, including clinical trial failures and competition from larger pharmaceutical companies. Success hinges on positive clinical trial outcomes and successful commercialization of its pipeline. They need to secure additional funding or partnerships for the pipeline to succeed.
Similar Companies
BMY
Bristol-Myers Squibb Company
BMY
Bristol-Myers Squibb Company
BNTX
BioNTech SE
BNTX
BioNTech SE
MRK
Merck & Company Inc
MRK
Merck & Company Inc
Sources and Disclaimers
Data Sources:
- Pyxis Oncology Investor Relations
- SEC Filings
- Company Press Releases
- Market Research Reports
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Pyxis Oncology Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2021-10-08 | CEO, President, Chief Medical Officer & Director Dr. Lara S. Sullivan M.D., MBA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 44 | Website https://www.pyxisoncology.com |
Full time employees 44 | Website https://www.pyxisoncology.com | ||
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.